HER2 Breast Cancer
HER2 Breast Cancer
Advertisement
Lauren Dembeck, PhDGenetics & Breast Cancer | July 16, 2025
HER2DX predicts outcomes in early HER2+ breast cancer, adding prognostic value beyond standard clinical-pathologic factors.
Sara Tolaney, MD, MPHHER2 Breast Cancer | July 14, 2025
Dr. Sara Tolaney explores how DESTINY-Breast09 may reshape first-line treatment in HER2+ metastatic breast cancer.
Maryam Lustberg, MD, MPHHER2 Breast Cancer | July 9, 2025
Dr. Maryam Lustberg discusses real-world T-DXd use, biomarkers, and resistance in metastatic breast cancer care.
Marina De Brot, MD, PhDHER2 Breast Cancer | July 8, 2025
AI-enhanced HER2 scoring improves accuracy and may expand patient access to HER2-targeted therapies in breast cancer care.
Kelly McCann, MD, PhDHER2 Breast Cancer | July 7, 2025
Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management.
Madison Johnson, BSHER2 Breast Cancer | July 3, 2025
Top research highlights from ESMO Breast Cancer 2025 showcase advances in treatment and care for patients with breast cancer.
Marina De Brot, MD, PhDHER2 Breast Cancer | July 8, 2025
AI-assisted platform boosts accuracy in identifying HER2-low breast cancer, improving access to targeted therapies.
Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 30, 2025
Cross-resistance data raise questions about sequencing ADCs in mBC; Dr. Lustberg discusses real-world outcomes and next steps
Sibylle Loibl, MDHER2 Breast Cancer | June 18, 2025
DESTINY-Breast09 shows promising PFS with T-DXd + pertuzumab vs THP in HER2+ MBC, but safety and sequencing raise questions.
Rebecca Shatsky, MDHER2 Breast Cancer | June 10, 2025
Dr. Shatsky weighs DESTINY-Breast09 findings and highlights the need to balance efficacy with long-term quality of life.
Rupert Bartsch, MDHER2 Breast Cancer | June 6, 2025
HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD.
Maryam Lustberg, MD, MPHHER2 Breast Cancer | June 5, 2025
Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment.
Stephanie L. Graff, MDHER2 Breast Cancer | June 5, 2025
Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
William J. Gradishar, MDHER2 Breast Cancer | June 5, 2025
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025.
Yvette C. TerrieHER2 Breast Cancer | June 3, 2025
T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09.
Yvette C. TerrieHER2 Breast Cancer | June 3, 2025
THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial.
Yvette C. TerrieHER2 Breast Cancer | May 31, 2025
T-DXd improves PFS and cORR over chemo in HER2-low/ultralow HR+ mBC, regardless of PI3K, ESR1, or BRCA1/2 mutations.
Yvette C. TerrieHER2 Breast Cancer | May 31, 2025
T-DXd rechallenge after grade 1 ILD showed high success and prolonged benefit, with low recurrence and no grade 5 events.
Lauren Dembeck, PhDHER2 Breast Cancer | May 31, 2025
Trastuzumab rezetecan shows strong intracranial activity in HER2+ breast cancer with brain metastases in REIN trial.
Advertisement